[Skip to Content]
[Skip to Content Landing]
November 2014

Preclinical Biomarkers in Alzheimer DiseaseA Sum Greater Than the Parts

Author Affiliations
  • 1Laboratory of Behavioral Neuroscience, National Institute on Aging, Biomedical Research Center, Baltimore, Maryland
JAMA Neurol. 2014;71(11):1357-1358. doi:10.1001/jamaneurol.2014.2462

As clinical trials move to earlier stages of disease and focus on cognitively normal (CN) individuals with positive biomarkers of Alzheimer disease (AD) (eg, β-amyloid [Aβ]), it is critical to determine the relationship between these biomarkers and cognitive change. It is especially important to determine whether this cognitive change varies by biomarker status and whether sufficient cognitive change occurs to provide clinically meaningful outcomes during short follow-up intervals. For example, the recently initiated Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease trial1 is enrolling individuals who are CN but amyloid positive to assess the efficacy of an antiamyloid therapy on cognitive trajectories during a 3-year follow-up period.

First Page Preview View Large
First page PDF preview
First page PDF preview